Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Europe Backs Celgene’s Pomalidomide And Aegerion’s Lomitapide

This article was originally published in The Pink Sheet Daily

Executive Summary

Positive opinions from Europe's top drug assessment panel in May have included a long-acting "biobetter" lipegfilgrastim from Teva, a once-weekly HGH injection from Biopartners GmbH, and a smallpox vaccine developed by Bavarian Nordic with funding from the U.S. BioShield program.

You may also be interested in...



Aegerion’s Lojuxta Submission To Germany's IQWIG Disappoints

IQWIG’s review is now open for consultation, with Germany's top HTA body the G-BA expected to make a final decision about the benefits of the ultra-orphan in December.

Smallpox Discovery Prompts FDA Action Plan; Move To White Oak Unchanged

FDA scientist’s discovery of decades-old vials of smallpox at lab on NIH campus are a reminder of the unsettled debate on whether governments should keep smallpox stock to aid development of antivirals.

U.S. Biotech Ariad Builds European Presence For Imminent Iclusig Launches

A new Swiss HQ for its European business and country-focused medical marketing teams are part of U.S.-based Ariad's solo push into the region, to be followed by development of new indications and new cancer-targeted therapies.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM007466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel